| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8284300 | Maturitas | 2016 | 11 Pages |
Abstract
Use of unopposed estrogen, tibolone and sequential combined therapy increases the risk of endometrial cancer. Continuous combined therapy seems risk free, but possibly not when micronized progesterone is used.
Keywords
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Ageing
Authors
Lea L. Sjögren, Lina S. Mørch, Ellen Løkkegaard,